The Scientist

» FDA and immunology

Most Recent

image: Measles Vax’s Off-Target Effects

Measles Vax’s Off-Target Effects

By | May 11, 2015

Researchers find evidence that measles vaccines reduced deaths from other infectious diseases due to “immune amnesia.”

2 Comments

image: Outsmarting HIV

Outsmarting HIV

By | May 4, 2015

Small molecules that mimic the T-cell surface receptor CD4 could expose the virus to antibody-based immune responses.

0 Comments

image: Filippos Porichis: Immunoregulator

Filippos Porichis: Immunoregulator

By | May 1, 2015

Principal Investigator, Ragon Institute of MGH, MIT, and Harvard. Age: 33

0 Comments

image: Llamas as Lab Rats

Llamas as Lab Rats

By | May 1, 2015

From diagnostics to vaccines, llama antibodies point to new directions in HIV research.

0 Comments

image: Looking for Latent HIV

Looking for Latent HIV

By | May 1, 2015

Sequencing HIV integration sites suggests that clonally expanded T-cell populations may not be the main source of latent virus.

0 Comments

image: Soluble Signal

Soluble Signal

By | May 1, 2015

An immune protein previously thought to mark inactive T cells has a free-floating form that correlates with HIV disease progression.

0 Comments

image: Defeating the Virus

Defeating the Virus

By | May 1, 2015

Recent discoveries are spurring a renaissance in HIV vaccine research and development.

0 Comments

image: FDA Calls for Data on ALS Drug

FDA Calls for Data on ALS Drug

By | April 21, 2015

In the midst of a debate about an experimental drug’s early approval, the US Food and Drug Administration requests that full trial results be released.

1 Comment

image: Protein Spurs T-Cell Proliferation

Protein Spurs T-Cell Proliferation

By | April 17, 2015

A newly discovered protein promotes immunity to viruses and cancer by triggering the production of cytotoxic T cells.

1 Comment

image: ALS Drug Access Debated

ALS Drug Access Debated

By | April 7, 2015

Biotech company Genervon has requested accelerated approval for its experimental ALS drug after a small but promising Phase 2 trial. Patients advocate for its acceptance, while researchers urge caution.

2 Comments

Popular Now

  1. GM Mosquitoes Closer to Release in U.S.
  2. Judge Recommends Ruling to Block Internet Access to Sci-Hub
  3. Opinion: Microbiology Needs More Math
  4. Do Pathogens Gain Virulence as Hosts Become More Resistant?
RayBiotech